Literature DB >> 23684532

Revisiting the clinical and histopathological aspects of patients with chromoblastomycosis from the Brazilian Amazon region.

Carla Avelar-Pires1, Juarez Antonio Simoes-Quaresma, Geraldo Mariano Moraes-de Macedo, Marilia Brasil-Xavier, Arival Cardoso-de Brito.   

Abstract

BACKGROUND AND AIMS: Chromoblastomycosis is a chronic fungal infection caused by species of the family Dematiaceae. Fonsecaea pedrosoi is the most common etiological agent. The objective of this study was to describe the epidemiological and mycological profile of patients with chromoblastomycosis from the Amazon region of Brazil and to correlate the clinical forms with the histopathological findings and severity criteria.
METHODS: Sixty-five patients were submitted to mycological (direct, culture, and microculture) and histopathological (hematoxylin-eosin staining) examination. Severity of the disease was classified according to the criteria proposed by Carrión in 1950.
RESULTS: Most patients were males (93.8%) and laborers (89.2%). There was a predominance of verrucous lesions (55.4%), which were mainly found on the lower limbs (81.5%). Two major types of tissue reaction were observed: a granulomatous reaction characterized by the formation of suppurative granulomas rich in fungal cells, which were almost always seen in verrucous lesions, and a reaction characterized by the formation of tuberculoid granulomas with few parasites, which were mainly found in well-delimited erythematous plaque-like and cicatricial lesions (p = 0.0001). A peculiar type of organized mycotic granuloma was observed in 20 subjects. Suppurative granulomas were more frequently detected in severe lesions (p = 0.0189) and in lesions with a duration of >10 years (p = 0.0408).
CONCLUSIONS: These results suggest that verrucous lesions present a less competent inflammatory tissue response than patients who develop a well-formed tuberculoid reaction. The latter is associated with a more effective immune response as observed in the limited clinical forms of chromoblastomycosis.
Copyright © 2013 IMSS. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23684532     DOI: 10.1016/j.arcmed.2013.04.008

Source DB:  PubMed          Journal:  Arch Med Res        ISSN: 0188-4409            Impact factor:   2.235


  10 in total

Review 1.  CHROMOBLASTOMYCOSIS: A NEGLECTED TROPICAL DISEASE.

Authors:  Flavio Queiroz-Telles
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2015-09       Impact factor: 1.846

2.  Clinical and demographic profile of chromoblastomycosis in a referral service in the midwest of São Paulo state (Brazil).

Authors:  Gabriela Franco Marques; Paula Yoshiko Masuda; Juliana Martins Prazeres Sousa; Jaison Antônio Barreto; Patrick Alexander Wachholz
Journal:  An Bras Dermatol       Date:  2015 Jan-Feb       Impact factor: 1.896

3.  Accuracy of direct examination and culture as compared to the anatomopathological examination for the diagnosis of chromoblastomycosis: a systematic review.

Authors:  Jules Rimet Borges; Bárbara Álvares Salum Ximenes; Flávia Tandaya Grandi Miranda; Giordana Bruna Moreira Peres; Isabella Toscano Hayasaki; Luiz César de Camargo Ferro; Mayra Ianhez; Marco Tulio Antonio Garcia-Zapata
Journal:  An Bras Dermatol       Date:  2022-05-25       Impact factor: 2.113

4.  Chromoblastomycosis: tissue modifications during itraconazole treatment.

Authors:  Kátia Sheylla Malta Purim; Murilo Calvo Peretti; José Fillus; Marcia Olandoski
Journal:  An Bras Dermatol       Date:  2017 Jul-Aug       Impact factor: 1.896

5.  Modulation of the immune response by Fonsecaea pedrosoi morphotypes in the course of experimental chromoblastomycosis and their role on inflammatory response chronicity.

Authors:  Isaque Medeiros Siqueira; Raffael Júnio Araújo de Castro; Luiza Chaves de Miranda Leonhardt; Márcio Sousa Jerônimo; Aluízio Carlos Soares; Tainá Raiol; Christiane Nishibe; Nalvo Almeida; Aldo Henrique Tavares; Christian Hoffmann; Anamelia Lorenzetti Bocca
Journal:  PLoS Negl Trop Dis       Date:  2017-03-29

6.  Exophiala psychrophila: A new agent of chromoblastomycosis.

Authors:  Lina M Garzon; Lili J Rueda; Adriana Marcela Celis; Martha Cardenas; Marcela Guevara-Suarez
Journal:  Med Mycol Case Rep       Date:  2018-10-25

Review 7.  Chromoblastomycosis: an etiological, epidemiological, clinical, diagnostic, and treatment update.

Authors:  Arival Cardoso de Brito; Maraya de Jesus Semblano Bittencourt
Journal:  An Bras Dermatol       Date:  2018 Jul-Aug       Impact factor: 1.896

8.  Chromoblastomycosis: A case series from Eastern China.

Authors:  Sujun Liu; Huilin Zhi; Hong Shen; Wenwen Lv; Bo Sang; Qiuping Li; Yan Zhong; Zehu Liu; Xiujiao Xia
Journal:  PLoS Negl Trop Dis       Date:  2022-09-26

9.  Robust Phagocyte Recruitment Controls the Opportunistic Fungal Pathogen Mucor circinelloides in Innate Granulomas In Vivo.

Authors:  Sarah Inglesfield; Aleksandra Jasiulewicz; Matthew Hopwood; James Tyrrell; George Youlden; Maria Mazon-Moya; Owain R Millington; Serge Mostowy; Sara Jabbari; Kerstin Voelz
Journal:  MBio       Date:  2018-03-27       Impact factor: 7.867

10.  Early immune response against Fonsecaea pedrosoi requires Dectin-2-mediated Th17 activity, whereas Th1 response, aided by Treg cells, is crucial for fungal clearance in later stage of experimental chromoblastomycosis.

Authors:  Isaque Medeiros Siqueira; Marcel Wüthrich; Mengyi Li; Huafeng Wang; Lucas de Oliveira Las-Casas; Raffael Júnio Araújo de Castro; Bruce Klein; Anamelia Lorenzetti Bocca
Journal:  PLoS Negl Trop Dis       Date:  2020-06-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.